Authors: HOBAN CJ

Citation: Cj. Hoban, RECENT ADVANCES IN PRECLINICAL DRUG DEVELOPMENT IN MULTIPLE-SCLEROSIS, Expert opinion on therapeutic patents, 8(7), 1998, pp. 831-854

Authors: CANNELLA B HOBAN CJ GAO YL GARCIAARENAS R LAWSON D MARCHIONNI M GWYNNE D RAINE CS

Citation: B. Cannella et al., THE NEUREGULIN, GLIAL GROWTH-FACTOR-2, DIMINISHES AUTOIMMUNE DEMYELINATION AND ENHANCES REMYELINATION IN A CHRONIC RELAPSING MODEL FOR MULTIPLE-SCLEROSIS, Proceedings of the National Academy of Sciences of the United Statesof America, 95(17), 1998, pp. 10100-10105

Authors: MARCHIONNI MA KIRK CJ ISAACS IJ HOBAN CJ MAHANTHAPPA NK ANTON ES CHEN C WASON F LAWSON D HAMERS FPT CANOLL PD REYNOLDS R CANNELLA B MEUN D HOLT WF MATTHEW WD CHEN LE GISPEN WH RAINE CS SALZER JL GWYNNE DI

Citation: Ma. Marchionni et al., NEUREGULINS AS POTENTIAL-DRUGS FOR NEUROLOGICAL DISORDERS, Cold Spring Harbor Symposia on Quantitative Biology, 61, 1996, pp. 459-472